Hospital
The Hospital Authority of Habersham County
The Hospital Authority of Habersham County was paid $11.79M by Medicaid between Jan 2018 and Mar 2024, across 195 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoTHE HOSPITAL AUTHORITY OF HABERSHAM COUNTY
DEMOREST, GA 30535
DEMOREST, GA 30535
33aNPI1689736282assigned 12/14/2006
33bProvider typeRural Acute Care Hospital
28Total paid$11.79M
24GClaims360,720
24DCodes billed195
24AFirst – last monthJan 2018 – Mar 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 59,256 | $2.00M | |
| 2019 | 63,948 | $1.89M | |
| 2020 | 48,781 | $1.57M | |
| 2021 | 66,193 | $1.97M | |
| 2022 | 69,223 | $2.26M | |
| 2023 | 45,371 | $1.71M | |
| 2024incomplete | 7,948 | $396K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 22,328 | 20,071 | $3.74M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 11,819 | 10,068 | $2.10M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.7% | 10,623 | 9,887 | $1.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.6% | 4,561 | 3,945 | $777K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.8% | 4,567 | 3,847 | $325K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 2,409 | 2,178 | $314K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.4% | 4,567 | 4,361 | $282K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 2,095 | 1,847 | $214K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 3,134 | 2,740 | $192K |
| G0378 | Hospital observation service, per hour | 1.5% | 2,065 | 1,640 | $182K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 7,281 | 4,861 | $135K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 7,364 | 5,660 | $125K |
183 more codes
| 80053 | Comprehensive metabolic panel | 1.0% | 22,402 | $122K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 8,929 | $120K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,288 | $117K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,721 | $113K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,796 | $102K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,601 | $101K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,453 | $98K |
| 59025 | Fetal non-stress test | <1% | 1,719 | $93K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,722 | $90K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,114 | $89K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,052 | $81K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,530 | $71K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 777 | $57K |
| 84484 | <1% | 9,326 | $57K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 648 | $46K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 515 | $41K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,833 | $38K |
| 82553 | <1% | 6,035 | $36K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,659 | $36K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,283 | $36K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,656 | $34K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,457 | $33K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 505 | $24K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,472 | $24K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 174 | $24K |
| 84703 | <1% | 7,019 | $23K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 918 | $22K |
| 96376 | <1% | 2,817 | $22K | |
| 83690 | <1% | 6,252 | $21K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,785 | $19K |
| 73564 | <1% | 788 | $19K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 358 | $19K |
| 73610 | <1% | 773 | $18K | |
| 87040 | <1% | 2,912 | $18K | |
| 83880 | <1% | 1,212 | $18K | |
| 81001 | <1% | 10,120 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,864 | $17K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 326 | $16K |
| 83605 | <1% | 2,600 | $15K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,941 | $15K |
| 73630 | <1% | 804 | $14K | |
| 83735 | <1% | 4,553 | $14K | |
| 82550 | <1% | 6,379 | $13K | |
| APT15 | <1% | 1,209 | $13K | |
| S9123 | Nursing care, in the home; by registered nurse, per hour (use for general nursing care only, not to be used when cpt codes 99500-99602 can be used) | <1% | 262 | $13K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 698 | $12K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 169 | $12K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,989 | $11K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,917 | $11K |
| 80061 | Lipid panel | <1% | 1,216 | $11K |
| 93970 | <1% | 205 | $9K | |
| 82805 | <1% | 471 | $9K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 129 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,161 | $8K |
| 85379 | <1% | 1,791 | $8K | |
| 87186 | <1% | 1,762 | $8K | |
| 73030 | <1% | 292 | $8K | |
| 76801 | <1% | 123 | $8K | |
| 73130 | <1% | 344 | $7K | |
| 86140 | <1% | 2,268 | $7K | |
| 85730 | <1% | 2,890 | $7K | |
| 81003 | <1% | 6,033 | $7K | |
| 87077 | <1% | 1,622 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,939 | $7K |
| 85027 | <1% | 1,637 | $6K | |
| 73110 | <1% | 282 | $6K | |
| 85610 | <1% | 3,331 | $6K | |
| 84439 | <1% | 838 | $6K | |
| 82962 | <1% | 4,255 | $6K | |
| A0425 | Ground mileage, per statute mile | <1% | 274 | $6K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 169 | $6K |
| 36600 | <1% | 499 | $5K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 121 | $5K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 75 | $5K |
| 97161 | <1% | 82 | $5K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 614 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 825 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,252 | $4K |
| 84702 | <1% | 1,078 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 103 | $4K |
| 74018 | <1% | 354 | $4K | |
| 97162 | <1% | 246 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 139 | $4K |
| 87634 | <1% | 165 | $4K | |
| S9124 | Nursing care, in the home; by licensed practical nurse, per hour | <1% | 68 | $4K |
| 82150 | <1% | 679 | $3K | |
| 86901 | <1% | 872 | $3K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 29 | $3K |
| 94664 | <1% | 333 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 92 | $3K |
| 96367 | <1% | 387 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,959 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 434 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,027 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,250 | $3K |
| 96368 | <1% | 176 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,935 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 35 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 133 | $2K |
| 82803 | <1% | 110 | $2K | |
| 87430 | <1% | 459 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 36 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 132 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,460 | $1K |
| 73590 | <1% | 19 | $1K | |
| 87070 | <1% | 464 | $1K | |
| 76770 | <1% | 15 | $1K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 14 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,513 | $1K |
| 76813 | <1% | 12 | $1K | |
| 76820 | <1% | 14 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,021 | $988.13 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 578 | $954.36 |
| 29125 | <1% | 76 | $952.63 | |
| 84100 | <1% | 585 | $942.87 | |
| 72081 | <1% | 12 | $914.23 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 82 | $908.52 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 143 | $875.58 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 606 | $867.72 |
| 51702 | <1% | 87 | $847.58 | |
| 72110 | <1% | 25 | $836.66 | |
| 82608 | <1% | 88 | $796.47 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 820 | $774.09 |
| 71250 | <1% | 14 | $723.05 | |
| 85652 | <1% | 358 | $722.87 | |
| 73090 | <1% | 44 | $702.22 | |
| 74022 | <1% | 29 | $700.73 | |
| 82375 | <1% | 321 | $670.41 | |
| 90714 | <1% | 79 | $655.89 | |
| 87420 | <1% | 81 | $649.02 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 634 | $632.77 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 241 | $596.68 |
| 86900 | <1% | 455 | $596.30 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 28 | $409.53 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 192 | $409.22 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 18 | $400.30 |
| 73560 | <1% | 33 | $376.86 | |
| 73502 | <1% | 14 | $369.23 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,195 | $320.39 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 47 | $298.68 |
| 94760 | <1% | 517 | $282.12 | |
| 73140 | <1% | 25 | $259.68 | |
| 12001 | <1% | 13 | $257.68 | |
| 82746 | <1% | 30 | $216.04 | |
| 87088 | <1% | 65 | $197.54 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 15 | $182.70 |
| APT16 | <1% | 13 | $159.39 | |
| 82077 | <1% | 17 | $139.46 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 465 | $134.42 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 718 | $133.73 |
| 82330 | <1% | 111 | $127.95 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 339 | $123.69 |
| 73080 | <1% | 14 | $111.58 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 309 | $101.75 |
| 82565 | <1% | 112 | $91.30 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 29 | $90.44 |
| 82247 | <1% | 20 | $89.55 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 262 | $77.67 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 177 | $76.74 |
| 86885 | <1% | 13 | $76.37 | |
| 82728 | <1% | 14 | $66.36 | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 19 | $55.44 |
| 86677 | <1% | 12 | $54.54 | |
| 84132 | <1% | 137 | $51.28 | |
| 83540 | <1% | 13 | $40.84 | |
| 82270 | <1% | 15 | $40.00 | |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 50 | $32.99 |
| 84295 | <1% | 113 | $28.23 | |
| 82947 | <1% | 112 | $26.98 | |
| 82435 | <1% | 96 | $25.00 | |
| 83615 | <1% | 16 | $22.37 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 60 | $14.23 |
| 1111F | <1% | 86 | $0.22 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 57 | $0.00 |
| 3078F | 0% | 42 | $0.00 | |
| 84145 | 0% | 106 | $0.00 | |
| 1160F | 0% | 18 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 60 | $0.00 |
| 85384 | 0% | 13 | $0.00 | |
| 1159F | 0% | 18 | $0.00 | |
| 3074F | 0% | 48 | $0.00 | |
| 3008F | 0% | 44 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, STEPHEN (CEO)
Parent organizationTHE HOSPITAL AUTHORITY OF HABERSHAM COUNTY
| Provider | Location | Paid |
|---|---|---|
| Southeastern Oklahoma Social Services INC. | Mcalester, OK | $1.74M |
| Stephen a Williams, M.D., INC. | Tampa, FL | $1.06M |
| Steelhead Specialty Group, PC | Roseburg, OR | $689K |
| A-1 Medicaid Dental Group | Bicknell, IN | $603K |
| Unique Rehabilitation Services INC. | Battle Creek, MI | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.